Insulet touts Omnipod Horizon glucose control system in kids with Type I diabetes
Insulet (NSDQ:PODD) touted additional data from the 1st feasbility study of its Omnipod Horizon hybrid closed-loop system last week at the ADA meeting. The company first presented results from the trial in February, showing that the personalized model predictive control algorithm performed well and was safe for adults with Type I diabetes.
The data presented last week demonstrated that pediatric and adolescent populations also experienced good results with the company’s automated glucose control system.
The study, which lasted for 36 hours, evaluated patients using a modified version of Insulet’s Omnipod system, a Dexcom continuous glucose sensor and the company’s personalized MPC algorithm . The study included 24 adults, 12 adolescents and 12 pediatric participants with Type I diabetes.
The company reported that the pediatric and adolescent groups achieved 70% of time spent in the target blood sugar range overall and at least 85% of time spent in the target range overnight.
Insulet said these findings support the algorithm’s performance in pediatric populations with high insulin sensitivity.
“We are thrilled to see positive results that show the potential of the Omnipod Horizon to improve clinical outcomes among pediatric and adolescent age groups in addition to the adult population, especially because of the unique challenges children with Type I diabetes face,” VP and medical director Dr. Trang Ly said in prepared remarks. “The early findings indicate this hybrid closed-loop algorithm has demonstrated good improvements in glycemic control during the day and night and we are looking forward to further advances with this extremely promising system.”
“This new data for our Omnipod Horizon Automated Glucose Control System illustrates that the technology is a potentially exciting solution for providing exceptional glucose control for people of all ages who are living with Type I,” president & chief operating officer Shacey Petrovic added. “Insulet is committed to improving the lives of people with diabetes, and we’re delighted to see the tremendous potential impact Horizon could have on improving the quality of life and clinical outcomes for Podders.”
